Axis Wealth Partners LLC Invests $290,000 in Pfizer Inc. (NYSE:PFE)

Axis Wealth Partners LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,924 shares of the biopharmaceutical company’s stock, valued at approximately $290,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blake Schutter Theil Wealth Advisors LLC raised its position in Pfizer by 33.2% during the 4th quarter. Blake Schutter Theil Wealth Advisors LLC now owns 13,889 shares of the biopharmaceutical company’s stock valued at $368,000 after purchasing an additional 3,461 shares in the last quarter. Naviter Wealth LLC raised its holdings in shares of Pfizer by 18.6% in the 4th quarter. Naviter Wealth LLC now owns 60,033 shares of the biopharmaceutical company’s stock valued at $1,593,000 after purchasing an additional 9,408 shares in the last quarter. Marble Harbor Investment Counsel LLC raised its holdings in shares of Pfizer by 5.4% in the 4th quarter. Marble Harbor Investment Counsel LLC now owns 356,809 shares of the biopharmaceutical company’s stock valued at $9,466,000 after purchasing an additional 18,254 shares in the last quarter. Rialto Wealth Management LLC bought a new position in Pfizer in the fourth quarter worth approximately $26,000. Finally, Lifeworks Advisors LLC raised its stake in Pfizer by 26.2% in the fourth quarter. Lifeworks Advisors LLC now owns 246,624 shares of the biopharmaceutical company’s stock worth $6,543,000 after buying an additional 51,184 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PFE. Wolfe Research began coverage on Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, Guggenheim reiterated a “buy” rating and set a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

Shares of NYSE PFE opened at $26.71 on Friday. The stock has a market cap of $151.35 billion, a price-to-earnings ratio of 18.94, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a 50 day simple moving average of $26.30 and a two-hundred day simple moving average of $27.24. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the firm earned $0.10 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were paid a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date was Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.44%. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.